|
|
12 Health Care Stocks Moving In Monday's Pre-Market Session
|
|
|
|
Novo Nordisk Stock Hits 52-Week Low After Weight-Loss Drug Falls Short Against Eli Lilly's
|
|
|
|
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 33%; Here Are 20 Stocks Moving Premarket
|
|
|
|
Novo Nordisk's Headline Results From REDEFINE 4 Phase 3 Trial Of Cagrisema Shows 23% Weight Loss After 84 Weeks Of Treatment, Also Cagrisema 2.4/2.4 mg Did Not Meet The Primary Endpoint Of Showing Non-inferiority On Weight Loss Compared To Tirzepatide 15 mg At 84 Weeks
|
|
|
|
Hims & Hers Health $1 Billion Eucalyptus Acquisition Fuels Global Expansion Dreams
|
|
|
|
Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms
|
|
|
|
Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market
|
|
|
|
Bloomberg Reported Novo Nordisk To Make Wegovy Pill In Ireland For Markets Outside US
|
|
|
|
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs
|
|
|
|
'Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials' - Bloomberg
|
|